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ABSTRACT
Prosthetic joint infections are an uncommon complication of joint replacement surgery, but are
associated with signiﬁcant morbidity and costs when they do occur. Gram-positive cocci, in particular
Staphylococcus aureus and Staphylococcus epidermidis, are the most commonly recovered microorganisms
(‡50% of all isolates). About 60% of prosthetic joint infections probably occur by direct contamination
during the operative procedure. Certain systemic conditions in the patients, as well as foreign material,
have been identiﬁed as risk factors for prosthetic joint infection. The clinical diagnosis is only certain
when there are sinus tracts that reach the prosthesis or purulent secretion is obtained from joint
aspiration or during open surgery. The treatment of an infected joint prosthesis must be individualised,
but it generally involves both systemic antibiotics and surgical intervention. Exchange arthroplasty in
one or two stages continues to be the standard approach to management. Prosthesis retention, in
conjunction with debridement and prolonged (for at least 3 months) oral antibiotic therapy, can be an
alternative for early postoperative or late acute haematogenous infections, when the duration of
symptoms is less than 1 month, the implant is stable, and the pathogen is relatively avirulent and
sensitive to an orally well absorbed antibiotic. Good results have been achieved under these conditions
in staphylococcal infections with rifampin associated with quinolones and other antibiotics, e.g.,
cotrimoxazole, fusidic acid, and linezolid.
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INTRODUCTION
Infection following joint arthroplasty is an
uncommon (1–2% of total joint replacements),
but frightening complication because it is associ-
ated high rates of morbidity and medical costs.
Patients can suffer up to three interventions
(implantation, removal and re-implantation),
and sometimes this may result in a poor func-
tional outcome (deﬁnitive excision arthroplasty of
the hip and arthrodesis of the knee). Treatment of
infections resulting from joint arthropasty has
been estimated at a minimum of $50 000 per
patient and $250 million per year in the United
States [1,2].
Certain risk factors have been identiﬁed for
prosthetic joint infection: prior surgery at the site
of the prosthesis; rheumatoid arthritis; immuno-
compromised states; diabetes mellitus; poor nutri-
tional status; obesity; psoriasis; long-term urinary
catheterisation; and extreme age [3,4]. About 60%
of prosthetic joint infections probably occur bec-
uase of direct contamination during the operative
procedure by microorganisms from the patient’s
skin and ⁄ or that of the operating room staff, or
airborne pathogens in the operating room. The
risk of infection is increased by any factor that
delays wound healing (e.g., necrosis, wound
haematomas and wound infection) since during
the early postimplantation period the fascial
layers have not yet healed and the periprosthesis
tissue is not protected. There are also other routes
of infection: contiguous spread from infected
overlying tissue; haematogenous dissemination
from the mouth, respiratory tract, urinary tract,
gastrointestinal tract, and the skin and soft tissue
infections; direct implantation by open trauma or
surgery; and reactivation during implantation of
latent foci of chronic and quiescent osteomyelitis
due to Staphylococcus aureus and Mycobacterium
tuberculosis [5,6].
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The metallic prosthesis, and particularly the
polymethylmethacrylate cement, predispose to
infection by persistence of bacteria on an avascu-
lar bone–cement interface which leukocytes, anti-
bodies and complement cannot reach, and by
local inmunological inhibition. Hence, the inocu-
lum necessary to establish infection is less [7–9].
S. aureus and coagulase-negative staphylococci
are the most common infecting agents associated
with prosthetic joint infections, and constitute
c. 50% of all isolates, although there are unlimited
numbers of causative pathogens. The frequency
varies among the published series [6,10–13].
Other microorganisms are recovered in late joint
infections after haematogenous dissemination
from genitourinary and gastrointestinal tract pro-
cedures or infections (Gram-negative rods, enter-
ococci, and anaerobes), dentogingival processes
or manipulations (viridans streptococcal, Pepto-
coccus and Peptostreptococcus), and pyogenic skin
infections (staphylococci and Streptococcus spp.).
Polymicrobial, mycobacterial and fungal aetiol-
ogy are unusual [6,13,14].
After implantation, a layer of glycoprotein
begins to cover the prosthesis which can enhance
bacterial adherence to the surface of the implant.
Staphylococci are probably the principal causative
agents because of receptors for these proteins [15].
Once adherant to the implant, many bacteria
develop a ﬁbrous exopolysaccharide (glycocalyx)
which forms a complex bioﬁlm. Within bioﬁlms
bacteria live and multiply in different phases of
growth (planktonic and stationary) into organ-
ised, complex communities with structural and
functional heterogeneity, resembling multicellular
organisms, and protected from antibiotics and
leukocytes [16–22].
Prosthetic joint infections can be classiﬁed in
relation to time of onset after surgery as: early
(<1 month); delayed (2–6 months); or late
(>6 months). Each type has etiopathogenic prop-
erties that inﬂuence the therapeutic options
(Table 1) [23].
The clinical presentation of prosthetic joint
infections is quite varied depending on the type
and location of the infection and the virulence
of the infecting organism, which may make the
diagnosis difﬁcult. The principal symptoms are
pain, swelling, warmth and erythema with a wide
spectrum of severity. When prosthetic joint infec-
tion begins in the immediate postoperative per-
iod, it may be difﬁcult to differentiate from
infection of the overlying tissues. Nonvirulent
microorganisms, such as S. epidermidis or dipther-
oides, sometimes cause infections clinically indis-
tinguishable from aseptic loosening, particularly
when pain is the only symptom. Joint pain related
to aseptic loosening occurs more readily with
motion or when bearing weight, while constant
joint pain that increases in intensity over time is
more suggestive of infection [11,24].
The criteria for the diagnosis have not currently
been established. The clinical diagnosis is only
certain when there are sinus tracts that reach the
prosthesis or purulent secretion is obtained from
joint aspiration or during open surgery [23].
Elevations of the erythrocyte sedimentation rate
(ESR) and C-reactive protein level (CRP),
although suggestive, are nonspeciﬁc and inad-
equate for diagnosis [25–27]. Nor are radiological
abnormalities very useful, because 3–6 months
may be required for them to appear and they can
also be seen commonly with aseptic loosening
[11,28,29]. Radionuclide scans with agents such as
technetium-99 m-labelled methylene diphospho-
nate have very high sensitivity but lack speciﬁcity
for infection. Bone scans can remain positive for
up to 6 months after implantation because of
increased periprosthetic bone remodelling.
Hence, a positive radionuclide scan is not deﬁn-
itive in establishing the infection, but a normal or
negative scan has a reliable negative predictive
value for arthroplasty infection [26,30–32]. Com-
puted tomography (CT) has limited use due to
imaging artefacts caused by metal implants,
and magnetic resonance imaging (MRI) can be
Table 1. Classiﬁcation of prosthetic joint infections
Category Early Delayed Late
Presenting
after surgery
1st month 2nd)6th month > 6th month
Acquisition During implantation During implantation Haematogenous
Aetiology Staphylococcus aureus, Streptococcus spp., GNB Staphylococcus epidermidis Staphylococcus aureus, Streptococcus spp.,
Staphylococcus epidermidis, bacilli
Treatment Retentiona Remove Retentiona
aIf duration of symptoms is < 1 month, prosthesis is stable, and pathogen is susceptible to oral antibiotics with activity against surface-adhering microorganisms.
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performed only in prostheses composed of tita-
nium or tantalum, although its usefulness decrea-
ses in the presence of metallic materials [26].
Positron-emission tomography with ﬂudeoxyglu-
cose F 18 is still in the development phase for
implant imaging [33]. Recovery of the bacteria by
aspiration of joint ﬂuid or from tissue obtained
during surgery remains the standard for the
diagnosis of arthroplasty infection. Multiple spec-
imens (at least three) should be obtained and
rapidly cultured in appropriate media [26,34–36].
Swab cultures have a low sensitivity and should
be avoided. Gram staining of synovial ﬂuid and
periprosthetic tissue has a low sensitivity (25–
30%). Cultures from aspirated synovial ﬂuid and
periprosthetic tissue provide the most reliable
means of detecting pathogens. In arthrocentesis
the pathogen can be detected in 45–100% of cases,
and the sensitivity of intraoperative cultures
ranges from 65 to 94% [37]. Cultures may give a
false negative result for several reasons: adher-
ence of bacteria to the prosthesis itself within the
surrounding glycocalyx; prior antimicrobial expo-
sure; a low number of organisms; an inappropri-
ate culture medium; fastidious organisms; or
prolonged transport to the microbiology laborat-
ory [37]. Cultures of a superﬁcial wound or sinus
tract are often positive because of microbial
colonisation from the surrounding skin and
should therefore be avoided [26,37,38]. Studies
with PCR to detect bacterial ribosomal RNA are
still experimental but they have demonstrated
high sensitivity [39]. Histopathological examina-
tion of periprosthetic frozen tissue to detect more
than ﬁve neutrophils per high-power ﬁeld at a
magnication of x400 has a very high sensitivity
and speciﬁcity of more than 80% and 90%,
respectively [37,40–41].
TREATMENT
The management of infection associated with a
prosthetic joint infection has not been standard-
ised [42]. Antibiotics should always be associated
with surgery. The problem is to know exactly
what type of surgical procedure is the best in each
case. The determination of optimal treatment
depends on: stability of the prosthesis; type of
infection; causative microorganism and the pos-
sibility of oral treatment; medical comorbidities to
allow for multiple surgical procedures; and sur-
gical limitations [23,42–44]. Ideally, the antimicro-
bial agent should have bactericidal activity
against surface-adhering, slow-growing, and bio-
ﬁlm-producing microorganisms [20,44–46]. At the
beginning of treatment, the intravenous route is
preferred over the oral route. This allows higher
serum antibiotic concentrations to be obtained, as
well as better antibiotic levels in bone. However,
rifampin, clindamycin, cotrimoxazole, quinolones
(e.g., levoﬂoxacin), fusidic acid and linezolid, in
general, have excellent bioavailability and achieve
good results when used orally in bone infection
[47–53]. Empirical antibiotic therapy can be initi-
ated while cultures are pending, particularly
when prosthetic joint infection begins in the
immediate postoperative period. Given the high
incidence of staphylococci and methicillin-resist-
ant staphylococci implicated in prosthetic joint
infections, teicoplanin or vancomycin, associated
or not with rifampin, are appropriate options. In
addition to glycopeptides, Gram-negative antibi-
otic coverage, including that for Pseudomonas
aeruginosa, should be ensured in patients with
sepsis. Good choices include cefepime, piperacil-
lin-tazobactam or levoﬂoxacin [23]. Once antibi-
otic sensitivities are available from cultured
organisms, antibiotic therapy should be adjusted.
In patients with sterile joint aspirates or intraop-
erative cultures, but with high suspicion of
prosthetic joint infection, two approaches are
feasible: continuation of treatment and debride-
ment; or observation. Nowadays there is no
scientiﬁc evidence that favours a speciﬁc ap-
proach in these cases.
Exchange arthroplasty, in one or two stages, and
aggressive resection of all infected tissue continues
to be the standard approach to management of the
infected prosthesis. There are no prospective trials
comparing the two surgical procedures. One-stage
revision includes removal of the foreign material
and reimplantation of a new prosthesis, preferably
with antibiotic-impregnated cement, during the
same operation [43,54]. This allows earlier mobil-
ity but the risk of recurrence of infection is greater.
Good results have been reported inmore than 80%
of patients. Systemic antibiotics are administered
rarely and without standardisation in this regimen
[5,55–57]. It has been suggested that this alternat-
ive therapy should be used only if certain condi-
tions are met: no need of allograft bone; no ﬁstula
present; satisfactory condition of soft tissue;
absence of difﬁcult-to-treat bacteria, e.g., methicil-
lin-resistant S. aureus (MRSA) or P. aeruginosa; and
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extensive debridement [42–44,58,59]. Two-stage
exchange arthroplasty is the preferred method of
most surgeons but needs adequate bone stock and
the absence of severe coexisting illnesses. The
implantation of the new prosthesis is delayed for a
variable period depending on the causative patho-
gen and the surgeon, although a minimum inter-
val of 6 weeks is accepted, during which systemic
antibiotic therapy, selected on the basis of quan-
titative in-vitro susceptibility studies, is underta-
ken (Table 2), and an antimicrobial-impregnated
temporary spacer is placed to keep the limb at the
correct length and to allow partial joint mobility.
Once the results of diagnostic studies indicate
eradication of the infection, a new cemented or
cementless prosthesis is implanted [42–44,60–65].
The disappearance of symptoms and decline in the
CRP level seem to be the best indicators for
monitoring the effectiveness of antibiotic therapy
[44]. Discontinuation of antimicrobial therapy in
order to obtain reliable samples at the time of
reimplantation to detect remaining infection is
controversial [5,42–44,66,67]. With this method,
the success rate is more than 90%, but the rates of
cost and morbidity are higher than in one-stage
revision, due to prolonged hospitalisation and
immobilisation of the patient, who is typically
elderly [44].
Debridement (eradication of infected tissue,
exchange of the polyethylene insert and large
volume pulsatile irrigation with physiological
serum or antiseptic solution) and prosthesis
retention, in conjunction with prolonged systemic
antibiotic therapy for at least 3 months, is an
alternative that is useful, particularly, for infec-
tions occurring less than 1 month after implanta-
tion or late acute haematogenous infection. It is an
attractive option for elderly patients since it
reduces morbidity, immobilisation, and costs.
This approach is advisable in patients who do
not have sepsis; whose prosthesis is not loose;
whose duration of symptoms is less than 1 month;
whose soft tissue is in good condition; whose
aetiology is staphylococcal or streptococcal; and
for whom an oral antibiotic with good bioavail-
ability and activity against bioﬁlm micro organ-
isms is available (Table 3) [42–44,68–74]. The
stability of the implant, the type of microorgan-
ism, and a short interval between the onset and
debridement are the principal predicting factors
for success with this therapeutic strategy [23,42–
44,70]. The studies performed on this therapeutic
option are different in terms of patient-selection
criteria, deﬁnition of infection, type of surgical
procedure, class of antibiotic, duration of therapy,
kind of devices, and duration of follow-up, all of
which confuse the interpretation of the results.
Rifampin is the cornerstone for this alternative,
since it has all qualities needed to treat bioﬁlm
microorganisms: it is active against staphylococci,
including MRSA; it can be administered orally;
and it has excellent tolerability and bioavailability
[47]. Its effectiveness had been proved in vitro, in
animal models, and in clinical studies with a rate
of cure over 50% [47,75–80], but it should never
be given alone because, unfortunately, staphylo-
cocci readily develop resistance by a single point
mutation in DNA-dependant RNA polymerase,
particularly if the microbial inoculum is high. The
natural rate of intrinsic resistance of staphylococci
to rifampin is 1 in 107 colony-forming units
[75,78,81,82]. Ideally, rifampin should be admin-
Table 2. Treatment of prosthetic joint infection with removal of implant by common microorganisms
Microorganism 1st choice Alternative choice
Staphylococcus MS Cloxacillin 2 g ⁄ 4–6 h IV
Cefazolin 1–2 g ⁄ 8 h IV Cefalexin 0.5–1 g ⁄ 8 h PO
Clindamycin 600 mg ⁄ 8 h IV
Teicoplanin 600 mg ⁄ 24 h IV ⁄ IM O
Levoﬂoxacin 750 mg ⁄ 24 h IV ⁄PO + Rifampin 600 mg ⁄ 24 h PO
Staphylococcus MR Teicoplanin 600 mg ⁄ 24 h IV ⁄ IM
Linezolid 600 mg ⁄ 12 h IV ⁄VO
Rifampin 600 mg ⁄ 24 h PO
Levoﬂoxacin 750 mg ⁄ 24 h IV ⁄PO O
Streptococcus spp. PS Penicillin G 5 · 106 U ⁄ 6 h IV
Ceftriaxone 2 g ⁄ 24 h IV Amoxicillin 750–1000 mg ⁄ 8 h PO
Co-trimoxazole 1 tablet ⁄ 8 h PO
Teicoplanin 600 mg ⁄ 24 h IV ⁄ IM
Enterococcus spp. PS Penicillin G 5 · 106 U ⁄ 6 h IV O
Ampicillin 2 g ⁄ 4–6 h IV +
Gentamicin 1 mg ⁄ kg ⁄ 8 h IV
Teicoplanin 600 mg ⁄ 24 h IV ⁄ IM + Gentamicin 1 mg ⁄ 8 h IV
Enterobacteriaceae Ceftriaxone 2 g ⁄ 24 h IV
Levoﬂoxacin 750 mg ⁄ 24 h IV ⁄PO
Aztreonam 2 g ⁄ 8 h IV
Pseudomonas aeruginosa Cefepime 2 g ⁄ 8 h IV
Piperacillin ⁄ tazobactam 4.5 g ⁄ 8 h
IV Imipenem 500 mg ⁄ 6–8 h IV
Levoﬂoxacin 500 mg ⁄ 12 h IV ⁄PO
MS, methicillin-susceptible; MR, methicillin-resistant; PS, penicillin-susceptible.
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istered in combination with another antibiotic
active against staphylococci and with similar
pharmacokinetic properties. Rifampin and a
ﬂuoroquinolone is a good combination and the
most used, since it can be orally administered, is
well tolerated, and in addition, both antibiotics
achieve high levels intracellularly, sufﬁcient to
kill Staphylococcus spp. in this location [83]. How-
ever, before the start of treatment, the antimicro-
bial susceptibility of the microorganism must be
known. Prior good clinical experiences with small
numbers of patients have recently been conﬁrmed
in other larger studies [78,84,85]. Drancourt et al.,
in a prospective cohort study in Staphylococcus-
infected orthopaedic implant patients with a long-
term combination of oral oﬂoxacin and rifampin,
reported an overall success rate of 74% (35 ⁄ 47),
and in 62% (13 ⁄ 21) of the patients, without
prosthesis removal. Most failures were due to
resistant staphylococci (in three cases a species
identical to the original, and in six, was a different
species) [79]. Another approach was carried out
by Zimmerly et al., in another randomised, pla-
cebo-controlled, double-blind study in patients
with Staphylococcus-infected stable implants trea-
ted by initial debridement and long-term therapy
they proved a signiﬁcant cure rate (keeping the
prosthesis) (p = 0.02) of combination rifampin
ciproﬂoxacin (100%) over ciproﬂoxacin mono-
therapy (58%). Emergence of resistance to
ciproﬂoxacin (among 15 S. aureus and three
S. epidermidis) was observed in only four cases
(three methicillin-sensitive S. aureus and one
methicillin-sensitive S. epidermidis) in the ciproﬂo-
xacin monotherapy group, but not in the combi-
nation group [47]. Newer ﬂuoroquinolones, e.g.,
levoﬂoxacin,moxiﬂoxacin, or gatiﬂoxacin aremore
effective against Gram-positive microorganisms
than ciproﬂoxacin and oﬂoxacin, and they have a
better pharmacokinetic proﬁle, but few data are
available on their efﬁcacy and toxicity with long-
term therapy [86]. Levoﬂoxacin can be given
orally every 24 h, and it has a mean absolute
bioavailability of ‡99%, supporting the inter-
changeability of the oral and intravenous routes
[87]. Barberan et al., in a prospective cohort study
in Staphylococcus-infected orthopaedic implant
patients, with a long-term oral combination of
rifampin and levoﬂoxacin reported an overall
clinical and bacteriological success rate of 69.5%
(48 ⁄ 69), and 80% (16 ⁄ 20) for patients with pros-
thetic infection with short duration of symptoms
(£1 month). A signiﬁcant statistical difference
(p = 0.043) was observed in the clinical and
microbiological subanalyses among randomised
prosthetic infection groups according to duration
of the symptoms. Adverse reactions observed
were mainly mild or moderate and reversible [88].
Unfortunately, the use of ﬂuoroquinolones may
be limited because of the increasing resistance of
staphylococci, and alternative antimicrobial regi-
mens are needed. Drancourt et al., in a compar-
ative, nonrandomised clinical trial, reported a
success rate of 55% with a combination of
rifampin and fusidic acid, similar to that obtained
with rifampin and oﬂoxacino (11 ⁄ 20) [89]. Stein
et al. treated multidrug-resistant Staphylococcus-
infected orthopaedic implant patients with high-
dose oral cotrimoxazole, with a success rate,
retaining prosthesis, of 60.7% (17 ⁄ 28) [49]. More
recently, Bassetti et al., in a retrospective study of
linezolid in 20 patients with prosthetic joint
infection (MRSA, 14 strains; methicillin-resistant
coagulase-negative staphylococci, ﬁve strains;
and Enterococcus spp., one strain) who either
refused further surgical intervention or in whom
surgical removal was not feasible, reported a cure
rate of 80% (16 ⁄ 20). The overall duration of
treatment was 7.2 ± 2 weeks (range 6–10 weeks),
linezolid was well tolerated, and no drugs-related
events leading to discontinuation of treatment
were recorded [90]. There are no data on cotrim-
Table 3. Long-term antibiotic therapy with prosthesis retention
Microorganism 1st choice Alternative choice
Staphylococcus QS ⁄MS Rifampin 600 mg ⁄ 24 h IV ⁄PO + Levoﬂoxacin 750 mg ⁄ 24 h IV ⁄PO O Rifampin 600 mg ⁄ 24 h PO + Cefalexin
500–1000 mg ⁄ 8 h PO
Ciproﬂoxacin 750 mg ⁄ 12 h IV ⁄PO
Staphylococcus QR ⁄MR Linezolid 600 mg ⁄ 12 h IV ⁄PO O Co-trimoxazole 1 tablet ⁄ 8 h IV ⁄PO O Teicoplanin 600 mg ⁄ 24 h IV ⁄ IM + Rifampin
600 mg ⁄ 24 h PO
Fusidic acid 500 mg ⁄ 8 h IV ⁄PO ± Rifampin 600 mg ⁄ 24 h IV ⁄PO
Streptococcus PS Ceftriaxone 2 g ⁄ 24 h IV ⁄ IM Followed by: Amoxicillin 750–1000 mg ⁄ 8 h PO +
Rifampin 600 mg ⁄ 24 h PO
QR, quinolone resistant; QS, quinolone susceptible; MS, methicillin-susceptible; MR, methicillin-resistant; PS, penicillin-susceptible.
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oxazole and linezolid in combination with
rifampin. Successful treatment of Staphylococcus-
infected stable prostheses with retention of the
joint components has been achieved with other
antibiotics. Tsukayama et al., with debridement
and intravenous administration of antibiotics for
4 weeks, eradicated 71% (25 ⁄ 35 patients) of early
postoperative hip prosthetic infections without
removal of the prosthesis [91]. Segretti et al., in a
retrospective study of 18 patients with prosthetic
joint infection, treated with debridement and
varied prolonged oral suppressive antibiotic ther-
apy, achieved functional prosthetic retention in 15
cases [92].
Penicillin-susceptible streptococcal prosthetic
joint infections have been successfully treated,
with prosthesis retention, using intravenous peni-
cillin or ceftriaxone, followed by oral amoxicillin-
rifampin [74]. Two-step exchange remains the
rule for P. aeruginosa-infected prostheses,
although Brouqui et al., using a combination of
ceftazidime and ciproﬂoxacin, reported a cure in
four of ﬁve patients without removing the
implants [93].
Antibiotic therapy alone for long-term sup-
pression is a reasonable option for patients in
whom surgery is contraindicated for different
reasons or who refuse further procedures. Its goal
is to reduce the clinical manifestations rather
than eradicate the infection, and to preserve the
function of the joint. The prerequisites for long-
term suppressive antimicrobial therapy are:
stability of the prosthesis; relatively avirulent
pathogen sensitive to an orally well absorbed
antibiotic; absence of systemic infection; good
tolerability of oral antibiotic therapy; and com-
pliance of the patient. There are no guidelines
concerning the duration of this approach [92,94].
The suppressive approach is not without risk,
the main being the emergence of secondary
resistance, the extension of the localised septic
process to adjacent tissue or to become a systemic
infection despite continual antibiotic therapy, and
the potential side-effects of long-term antibiotic
therapy [95].
Arthrodesis of the knee, deﬁnitive excision
arthroplasty and Girdlestone resection of the hip
are currently rare options indicated in severe
and recalcitrant prosthetic infections, failure of
exchange arthroplasty, poor quality of bone and
soft tissues, highly resistant microorganisms,
patients unsuitable for more demanding recon-
struction, and those in whom arthroplasty will
not provide a functional beneﬁt. The efﬁcacy for
pain relief and cure of infection is moderate and
there is a poor functional outcome for both [96–
101].
Guidelines to control the efﬁcacy of treatment,
the potential side-effects of antibiotic therapy, and
follow-up have not been established. Clinical
observation, haematology, ESR, CRP, biochemis-
try analysis, samples for culture, and imaging
studies should take place weekly during the ﬁrst
month of treatment, and monthly thereafter.
During follow-up the assessment should take
place every 3 months for at least 1 year [23].
In summary, there is no single approach that is
best. Stability of the prosthesis, duration of the
symptoms, the pathogen recovered and its anti-
biotic susceptibility to oral antimicrobial agents
with activity against surface-adhering microor-
ganisms, condition of soft tissue, patient prefer-
ence, and health status need to be considered in
selecting the approach to therapy. Large-scale
multicentre trials are still necessary to determine
the inﬂuence of the multiple variables involved in
arthroplasty infections.
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